PMID- 28028895 OWN - NLM STAT- MEDLINE DCOM- 20171103 LR - 20181202 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 105 IP - 4 DP - 2017 Apr TI - Characterization of Sox9-overexpressing human umbilical cord blood-derived mesenchymal stem cells-based engineered cartilage both in vitro and in vivo. PG - 1150-1155 LID - 10.1002/jbm.a.35989 [doi] AB - The source of seed cells is a critical factor for tissue engineering. The goal of this study was to evaluate the chondrogenesis of Sox9-overexpressing human umbilical cord mesenchymal stem cells (hUCMSCs) seeded onto bone matrix gelatin (BMG)/fibrin hybrid scaffolds both in vitro and in vivo. hUCMSCs were stably transfected with Sox9-expressing plasmid and grown on the three-dimensional BMG/fibrin hybrid scaffold for 8 weeks. Scanning electron microscopy and histochemistry were performed. The hUCMSC-loaded scaffolds were implanted into the subcutaneous layer of immunocompetent rats and chondrogenesis and host immune responses were monitored for 8 weeks. We found that hUCMSCs spread well and proliferated from 2 weeks after culturing. They produced abundant glycosaminoglycans and collagen II. At 8 weeks after implanting into rats, the hUCMSCs on the scaffolds formed cartilage-like tissue and displayed positive staining for toluidine blue, safranin O, Masson's trichrome, and collagen II. No significant changes in serum levels of lgG, lgA, lgM, C3, and C4 were observed after implantation of the hUCMSC-loaded scaffolds. Xenogeneic implantation of Sox9-overexpressing hUCMSCs embedded in the BMG/fibrin scaffolds promotes the formation of cartilage-like tissue without inducing evident host immune response. Therefore, Sox9-overexpressing hUCMSCs represent a promising cell candidate for cartilage tissue engineering. (c) 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 1150-1155, 2017. CI - (c) 2017 Wiley Periodicals, Inc. FAU - Li, Xiao-Li AU - Li XL AD - Department of Dermatology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. FAU - Zhang, Jun AU - Zhang J AD - Department of Otolaryngology, The Affiliated Hospital of Yan'an University, Yan'an, China. FAU - Luo, Hua-Nan AU - Luo HN AD - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. FAU - Zhao, Xiao-Yan AU - Zhao XY AD - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. FAU - Zhang, A-Ling AU - Zhang AL AD - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. FAU - Wang, Zheng-Hui AU - Wang ZH AD - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710004, China. LA - eng PT - Journal Article DEP - 20170209 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (SOX9 Transcription Factor) RN - 0 (SOX9 protein, human) SB - IM MH - Animals MH - Cartilage/cytology/*metabolism MH - Fetal Blood/cytology/*metabolism MH - Heterografts MH - Humans MH - Mesenchymal Stem Cell Transplantation MH - Mesenchymal Stem Cells/cytology/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - SOX9 Transcription Factor/*biosynthesis MH - Time Factors MH - *Tissue Engineering MH - Tissue Scaffolds/*chemistry OTO - NOTNLM OT - chondrogenesis OT - immune rejection OT - mesenchymal stem cells OT - tissue engineering EDAT- 2016/12/29 06:00 MHDA- 2017/11/04 06:00 CRDT- 2016/12/29 06:00 PHST- 2016/10/31 00:00 [received] PHST- 2016/12/09 00:00 [revised] PHST- 2016/12/21 00:00 [accepted] PHST- 2016/12/29 06:00 [pubmed] PHST- 2017/11/04 06:00 [medline] PHST- 2016/12/29 06:00 [entrez] AID - 10.1002/jbm.a.35989 [doi] PST - ppublish SO - J Biomed Mater Res A. 2017 Apr;105(4):1150-1155. doi: 10.1002/jbm.a.35989. Epub 2017 Feb 9.